Application of PGC-1alpha in preparation of medicine for promoting hippocampal neurogenesis and supplementing lost neurons

By constructing a PGC-1α overexpression model in Alzheimer's disease mice, using PGC-1α protein or its agonist to promote hippocampal neurogenesis, the problem of impaired hippocampal neurogenesis was solved, and neuronal supplementation was achieved. New drug targets for the treatment of Alzheimer's disease.

CN119015398APending Publication Date: 2024-11-26ZHENJIANG JIESHENGRUI TECH CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410810220.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing Alzheimer's disease treatment drugs cannot effectively improve cognitive dysfunction and behavioral impairment, and cannot fundamentally solve the problem of impaired hippocampal neurogenesis, resulting in limited treatment.

Method used

By constructing PGC-1α overexpressing mice in the DG region of the hippocampus in Alzheimer's disease, using PGC-1α protein or its agonist or transgenic agent to induce PGC-1α overexpression, promote hippocampal neurogenesis and supplement lost neurons, and prepare Drugs that delay the progression of Alzheimer's disease.

Benefits of technology

Overexpression of PGC-1α can improve neurogenesis damage, supplement lost neurons, and provide new drug targets, which is of great significance to the research on the mechanism of Alzheimer's disease and the development of targeted drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015398A_ABST
    Figure CN119015398A_ABST
Patent Text Reader

Abstract

The invention provides application of PGC-1alpha in preparation of a medicine for promoting hippocampal neurogenesis and supplementing lost neurons, and belongs to the technical field of biological medicine. A PGC-1alpha overexpression mouse in the DG region of the hippocampus of the Alzheimer's disease is constructed, and experiments find that neurogenesis of the hippocampus of the mouse can be promoted by supplementing the reagent for inducing PGC-1alpha protein overexpression in the brain region of the mouse, and neural stem cells are induced to generate new neurons; the reagent for inducing PGC-1 alpha protein overexpression can be used for preparing the medicine for promoting hippocampal neurogenesis and supplementing lost neurons, neonatal neurons induced by the medicine supplement neuronal loss accompanied by neurodegeneration, a new medicine action target is provided for delaying disease progression or treating Alzheimer's disease, and the reagent has a good application prospect. The important significance is realized on the mechanism research of the Alzheimer disease and the targeted drug development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of PGC-1α in preparing drugs for promoting hippocampal neurogenesis and supplementing lost neurons. Background Art

[0002] Alzheimer's disease (AD) is an age-related neurodegenerative disease with memory loss and cognitive impairment as its main symptoms. Its mechanism includes impaired neurogenesis in addition to neuronal apoptosis and necrosis. Typical pathological manifestations of AD include neuronal amyloid deposition, Tau protein tangles, and irreversible neuronal apoptosis. Current drugs such as cholinergic inhibitors, commonly used ones like donepezil, NMDA receptor antagonists, commonly used ones like memantine, and some brain cell activators such as piracetam, aniracetam, and oxiracetam can only delay the progression of the disease, but cannot effectively improve or cure the cognitive dysfunction and behavioral impairment of AD. Studies have shown that impaired hippocampal neurogenesis in AD occurs earlier than its pathological deposition and neuronal apoptosis. Therefore, inducing neurogenesis in the adult hippocampus and replenishing lost neurons will fundamentally overcome the limitations of current AD treatment, which is of great significance for the development of AD targeted drugs and provides an important signal target for the mechanism research of neurodegenerative diseases.

[0003] Traditionally, it is believed that new neurons can only be generated in the brains of embryos and infants. After adulthood, neurons after mitosis exit the cell cycle, enter a quiescent state, and no longer proliferate. However, in recent years, neurobiologists have discovered that neural stem cells in the subventricular zone (SVZ) and subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus of healthy adults can still continue to generate new neurons after adulthood. This process is called adult neurogenesis. Adult neurogenesis is a multi-step physiological process, including the entire process of proliferation, differentiation, and migration of adult neural stem cells and neural progenitor cells to produce terminally differentiated mature neurons and integrate into the adult neural network. The occurrence of AD is not only closely related to neuronal apoptosis, but is often accompanied by impaired neurogenesis. Therefore, regulating the neurogenesis of the adult hippocampus has very important economic and social significance for the early diagnosis, treatment, and intervention of AD.

[0004] The Pgc-1alpha gene is located on chromosome 4 in humans (chromosome 5 in mice). The protein it encodes, PGC-1α, contains 798 (human) and 797 (mouse) amino acids. PGC-1α is widely present in the human body and is highly expressed in various tissues and organs that require high energy consumption, such as brown adipose tissue, skeletal muscle, heart, liver, kidney and brain. PGC-1α activates the expression of a large number of transcription factors that are closely related to mitochondrial respiration, mitochondrial energy metabolism and quality control, inhibits oxidative stress through multiple pathways, and protects cells from damage by reactive oxygen species.

[0005] Currently, there are no relevant studies and reports on the application of PGC-1α in promoting neurogenesis in the hippocampus of adult mice and replenishing lost neurons. Summary of the invention

[0006] In view of some deficiencies in the prior art, the present invention provides an application of PGC-1α in the preparation of drugs for promoting hippocampal neurogenesis and replenishing lost neurons; the present invention constructs a mouse with PGC-1α overexpression in the DG region of the hippocampus of Alzheimer's disease, and experiments show that supplementing the reagent that induces overexpression of PGC-1α protein in the mouse brain region can promote neurogenesis in the mouse hippocampus and induce neural stem cells to generate new neurons; the PGC-1α can be used to prepare drugs for promoting hippocampal neurogenesis and replenishing lost neurons, and the new neurons induced by the drug replenish the neuronal loss associated with neurodegeneration, providing a new drug target for delaying the progression or treatment of Alzheimer's disease, which is of great significance to the mechanism research of Alzheimer's disease and the development of targeted drugs.

[0007] In order to achieve the above technical objectives, the present invention adopts the following technical means:

[0008] The present invention firstly provides the application of PGC-1α in preparing medicine for promoting hippocampal neurogenesis and supplementing lost neurons.

[0009] Preferably, the nucleotide sequence of PGC-1α is as shown in SEQ ID No.1.

[0010] The present invention also provides a drug for promoting hippocampal neurogenesis and replenishing lost neurons, wherein the drug comprises PGC-1α protein, an agonist of PGC-1α or a transgenic agent for inducing overexpression of PGC-1α.

[0011] Preferably, the drug also includes reagents related to adeno-associated virus-induced PGC-1α transgene.

[0012] Preferably, the drug further comprises pharmaceutically acceptable excipients.

[0013] Preferably, the pharmaceutically acceptable excipient is selected from at least one of a buffer, an encapsulating agent, a filler, a binder, a transdermal absorbent, a wetting agent, a disintegrant, an absorption enhancer, a surfactant, a colorant, a flavoring agent and an adsorption carrier.

[0014] The present invention also provides the use of the above-mentioned drug for promoting hippocampal neurogenesis and replenishing lost neurons in the preparation of drugs for treating neurological diseases; the neurological diseases include diseases caused by neuronal apoptosis, necrosis or damage.

[0015] Preferably, the neurological disease comprises Alzheimer's disease.

[0016] Preferably, the Alzheimer's disease comprises pathological neuronal apoptosis or necrosis.

[0017] Preferably, the application includes:

[0018] (1) expanding the pool of neural stem cells in the hippocampus of Alzheimer's disease; and / or

[0019] (2) promoting the transformation of quiescent neural stem cells in the hippocampus of Alzheimer's disease into activated neural stem cells; and / or

[0020] (3) promoting the proliferation of intermediate progenitor cells in the hippocampus of Alzheimer's disease; and / or

[0021] (4) inducing differentiation of immature neurons in the hippocampus of Alzheimer's disease; and / or

[0022] (5) Inducing the generation of mature neurons in the hippocampus of Alzheimer's disease to replenish lost neurons; and / or

[0023] (6) Improve the impaired neurogenesis in Alzheimer's disease.

[0024] The present invention also provides a medicine for treating Alzheimer's disease, which comprises the above-mentioned medicine for promoting hippocampal neurogenesis and supplementing lost neurons.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention confirms through in vivo experiments that overexpression of PGC-1α can improve the damaged neurogenesis associated with AD and replenish lost neurons; the present invention clearly shows for the first time that overexpression of PGC-1α can promote hippocampal neurogenesis, so PGC-1α can be used to prepare drugs that promote hippocampal neurogenesis and replenish lost neurons. The newborn neurons induced by PGC-1α replenish the neuronal loss associated with neurodegeneration, providing a new drug target for delaying the progression of Alzheimer's disease or treating it, which is of great significance to the mechanism research of Alzheimer's disease and the development of targeted drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 It is a map of the overexpression vector pAAV-MCS-Ppargcla-m-FLAG-HA.

[0028] Figure 2 This is a diagram showing the results of PCR gene identification of APP / PS1 double transgenic mice; in the figure, numbers 3-4, 6, 8-9, 11-14, 16, and 18 represent B6; C3-Tg (APPswe, PSEN1dE9) 85Dbo / Mmjax mouse individuals; M is a DNA molecular marker.

[0029] Figure 3 Schematic diagram of the site-specific microinjection method in the hippocampus of APP / PS1 mice; the plasmids used for microinjection are: pAAV-MCS-Ppargc1α-m-FLAG-HA and pAAV-MCS-FLAG-Control.

[0030] Figure 4 This is the HE staining verification image of the injection site in the hippocampus of APP / PS1 mice. The injection site is (AP: -2.06mm, ML: ±1.70mm, DV: -2.00mm).

[0031] Figure 5 Immunofluorescence (a) and Western blotting (b) verify the overexpression of PGC-1α in the hippocampus of APP / PS1 mice, and the quantitative results of PGC-1α protein expression in Western blotting results (c); Figure 5 In a, green is HA-traced PGC-1α. Scale bar = 40 μm.

[0032] Figure 6 The effect of PGC-1α on the activation of neural stem cells in the hippocampus of APP / PS1 mice; Figure a shows the immunofluorescence monitoring of GFAP in quiescent neural stem cells + SOX2 + PCNA - and activated neural stem cells GFAP + SOX2 + PCNA + a, red light is GFAP:SOX2; green light is PCNA; purple light is DAPI, scale bar = 50 μm; b is the quantitative analysis of the number of neural stem cells in different states (quiescent state and activated state) in the hippocampus of transgenic mice.

[0033] Figure 7Figure 1 is the effect of PGC-1α on the proliferation of neural stem cells in the hippocampus of APP / PS1 mice; Figure a is immunofluorescence monitoring of neural stem cells (SOX2 + GFAP + ), red light is GFAP; green light is SOX2; purple light is DAPI, scale bar = 50 μm; b is the number of neural stem cells (SOX2 + GFAP + )’s quantitative analysis diagram.

[0034] Figure 8 The figure shows the effect of PGC-1α on the number of committed progenitor cells in the hippocampus of APP / PS1 mice; in the figure, a is the immunofluorescence display of proliferating neural progenitor cells, red light is Tbr2; green light is PCNA; purple light is DAPI, scale = 50μm; b is the quantitative analysis of the number of neural progenitor cells in the proliferative state; c is the protein expression and quantification of Tbr2 detected by Western blotting; d is the protein expression and quantification of PCNA detected by Western blotting.

[0035] Fig. 9 Figure 2 is the effect of PGC-1α on the differentiation of neurons in the hippocampus of APP / PS1 mice; a is immunofluorescence monitoring of newborn neurons in the hippocampus (DCX + NeuN - ), immature neurons (DCX + NeuN + ) and mature neurons (DCX - NeuN + ) differentiation, red light in a is NeuN, green light is DCX, and purple light is DAPI; b is the immunofluorescence result of newborn neurons (DCX + NeuN - ), immature neurons (DCX + NeuN + ) and mature neurons (DCX - NeuN + ) quantitative analysis of the number of cells; c is the protein expression and quantification of DCX detected by Western blotting; d is the protein expression and quantification of NeuN detected by Western blotting. DETAILED DESCRIPTION

[0036] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but the scope of protection of the present invention is not limited thereto. In the following embodiments, various processes and methods not described in detail are conventional methods known in the art. The sources, trade names, and components of the reagents used are indicated when they first appear, and the same reagents used thereafter are not specifically stated, and are the same as the sources indicated for the first time; the reagents, materials, etc. involved are not specifically stated, and are all obtained for commercial purposes.

[0037] Materials and Reagents:

[0038] APP / PS1 double transgenic mice, B6;C3-Tg(APPswe,PSEN1dE9)85Dbo / Mmjax, strain name B6C3, purchased from Jackson lab (No.34829-JAX, Jackson laboratory), 3 males and 3 females.

[0039] The transgenic mice were raised in accordance with the SPF animal breeding standards. After isolation and observation without abnormality, they were allowed to enter the breeding area, and experimental operations were carried out in strict accordance with the relevant SPF animal management regulations.

[0040] The construction and packaging of pAAV-MCS-Ppargc1α-m-FLAG-HA and pAAV-MCS-FLAG-Control plasmids were completed by Zhenjiang Aibimeng Biotechnology Co., Ltd.

[0041] In the following examples, the antibodies involved are: rabbit polyclonal PGC-1a (Beijing Bioson Biotechnology Co., Ltd., cat#bs-1832R, Beijing, China), mouse monoclonal HA (Beijing Bioson Biotechnology Co., Ltd., cat#bsm-33003M), rabbit polyclonal Glial fibrillary acid protein (GFAP) (Wanlei Biotechnology Co., Ltd., cat# WL0836, Shenyang, China) and mouse monoclonal GFAP (Wuhan Tri-Eagle Biotechnology Co., Ltd., cat# 60190-1-lg, Wuhan, China), mouse monoclonal SOX2 (Wuhan Tri-Eagle Biotechnology Co., Ltd., cat# 66411-1-lg), rabbit polyclonal Tbr2 (Wanlei Biotechnology Co., Ltd., cat# WL02728, Shenyang, China), mouse monoclonal NeuN (Wuhan Tri-Eagle Biotechnology Co., Ltd., cat# 66836-1-lg), rabbit polyclonal PCNA (Wanlei Biotechnology Co., Ltd., cat# WL03099, Shenyang, China), rabbit polyclonal DCX (Wuhan Tri-Eagle Biotechnology Co., Ltd., cat# 13925-1-AP), GAPDH (Beijing Bio-Osen Biotechnology Co., Ltd., cat# bs2188R), β-Tubulin (Aibimeng Biotechnology Co., Ltd., cat# G098, Zhenjiang, China). Secondary antibodies for Western blotting (HRP-labeled goat anti-mouse, cat#A0216; HRP-labeled goat anti-rabbit, cat#A0208, Bio-Time Biotechnology Co., Ltd., Shanghai, China) and secondary antibodies for immunofluorescence: DyLight 594-goat anti-rabbit IgG, DyLight 488-goat anti-rabbit IgG, DyLight 594-goat anti-mouse IgG, and DyLight 488-goat anti-mouse IgG were purchased from Boster Biotechnology Co., Ltd., Wuhan.

[0042] The nucleotide sequence of PGC-1α involved is shown in SEQ ID No.1.

[0043] SEQ ID No.1:

[0044] ATGGCTTGGGACATGTGCAGCCAAGACTCTGTATGGAGTGACATAGAGTGTGCTGCT

[0045] CTGGTTGGTGAGGACCAGCCTCTTTGCCCAGATCTTCCTGAACTTGACCTTTCTGAACT

[0046] TGATGTGAATGACTTGGATACAGACAGCTTTCTGGGTGGATTGAAGTGGTGTAGCGA

[0047] CCAATCGGAAATCATATCCAACCAGTACAACAATGAGCCTGCGAACATATTTGAGAA

[0048] GATAGATGAAGAGAATGAGGCAAACTTGCTAGCGGTTCTCACAGAGACACTGGACAG

[0049] TCTCCCCGTGGATGAAGACGGATTGCCCTCATTTGATGCACTGACAGATGGAGCCGTG

[0050] ACCACTGACAACGAGGCCAGTCCTTCCTCCATGCCTGACGGCACCCCTCCCCCTCAGG

[0051] AGGCAGAAGAGCCGTCTCTACTTAAGAAGCTCTTACTGGCACCAGCCAACACTCAGC

[0052] TCAGCTACAATGAATGCAGCGGTCTTAGCACTCAGAACCATGCAGCAAACCACACCC

[0053] ACAGGATCAGAACAAACCCTGCCATTGTTAAGACCGAGAATTCATGGAGCAATAAAG

[0054] CGAAGAGCATTTGTCAACAGCAAAAGCCACAAAGACGTCCCTGCTCAGAGCTTCTCA

[0055] AGTATCTGACCACAAACGATGACCCTCCTCACACCAAACCCACAGAAAACAGGAACA

[0056] GCAGCAGAGACAAATGTGCTTCGAAAAAGAAGTCCCATACACAACCGCAGTCGCAAC

[0057] ATGCTCAAGCCAAACCAACAACTTTATCTCTTCCTCTGACCCCAGAGTCACCAAATGA

[0058] CCCCAAGGGTTCCCCATTTGAGAACAAGACTATTGAGCGAACCTTAAGTGTGGAACT

[0059] CTCTGGAACTGCAGGCCTAACTCCTCCCACAACTCCTCCTCATAAAGCCAACCAAGAT

[0060] AACCCTTTCAAGGCTTCGCCAAAGCTGAAGCCCTCTTGCAAGACCGTGGTGCCACCGC

[0061] CAACCAAGAGGGCCCGGTACAGTGAGTGTTCTGGTACCCAAGGCAGCCACTCCACCA

[0062] AGAAAGGGCCCGAGCAATCTGAGTTGTACGCACAACTCAGCAAGTCCTCAGGGCTCA

[0063] GCCGAGGACACGAGGAAAGGAAGACTAAACGGCCCAGTCTCCGGCTGTTTGGTGACC

[0064] ATGACTACTGTCAGTCACTCAATTCCAAAACGGAT ATACTCA TT AACATATCACAGGA

[0065] GCTCCAAGACTCTAGACAACTAGACTTCAAAGATGCCTCCTGTGACTGGCAGGGGCA

[0066] CATCTGTTCTTCCACAGATTCAGGCCAGTGCTACCTGAGAGAGACTTTGGAGGCCAGC

[0067] AAGCAGGTCTCTCCTTGCAGCACCAGAAAACAGCTCCAAGACCAGGAAATCCGAGCG

[0068] GAGCTGAACAAGCACTTCGGTCATCCCTGTCAAGCTGTGTTTGACGACAAATCAGACAA

[0069] GACCAGTGAACTAAGGGATGGCGACTTCAGTAATGAACAATTCTCCAAACTACCT

[0070] GTGTTTATAAATTCAGGACTAGCCATGGATGGCCTATTTGATGACAGTGAAGATGAA

[0071] AGTGATAAACTGAGCTACCCTTGGGATGGCACGCAGCCCTATTCATTGTTCGATGTGT

[0072] CGCCTTCTTGCTCTTCCTTTAACTCTCCGTGTCGAGACTCAGTGTCACCACCGAAATCC

[0073] TTATTTTCTCAAAGACCCCAAAGGATGCGCTCTCGTTCAAGATCCTTTTCTCGACACA

[0074] GGTCGTGTTCCCGATCACCATATTCCAGGTCAAGATCAAGGTCCCCAGGCAGTAGATC

[0075] CTCTTCAAGATCCTGTTACTACTATGAATCAAGCCACTACAGACACCGCACACACCGC

[0076] AATTCTCCCTTGTATGTGAGATCACGTTCAAGGTCACCCTACAGCCGTAGGCCCAGGT

[0077] ACGACAGCTATGAAGCCTATGAGCACGAAAGGCTCAAGAGGGATGAATACCGCAAA

[0078] GAGCACGAGAAGCGGGAGTCTGAAAGGGCCAAACAGAGAGAGAGGCAGAAGCAGA

[0079] AAGCAATTGAAGAGCGCCGTGTGATTTACGTTGGTAAAATCAGACCTGACACAACGCGGACAGAA TTGAGAGACCGCTTTGAAGTTTTTGGTGAAATTGAGGAA TGCACCGTAA ATCTGCGGGATGATGGAGACAGCTATGGTTTCATCACCTACCGTTACACCTGTGACGC TTTCGCTGCTCTTGAGAATGGATATACTTTACGCAGGTCGAACGAAACTGACTTCGAG CTGT ACTTTTGTGGACGGAAGCAATTTTTCAAGTCT AACTA TGCAGACCTAGAT ACCAACTCAGACGATTTTGACCCTGCTTCCACCAAGAGCAAGTATGACTCTCTGGATTTTGA TAGTTTACTGAAGGAAGCTCAGAGAAGCTTGCGCAGG.

[0080] Example 1: Breeding and identification of APP / PS1 double transgenic mice (B6; C3-Tg (APPswe, PSEN1dE9) 85Dbo / Mmjax)

[0081] 1.1. Experimental animals and protocols:

[0082] APP / PS1 double transgenic mice, strain name B6; C3-Tg (APPswe, PSEN1dE9) 85Dbo / Mmjax, were purchased from Jackson Lab, USA, 3 males and 3 females.

[0083] SPF C57BL / 6J mice were purchased from the Experimental Animal Center of Jiangsu University [License No.: SCxk(Su)2015-0001].

[0084] APP / PS1 double transgenic mice were selected to mate with SPF-grade C57BL / 6J mice to expand the APP / PS1 population and obtain the offspring of transgenic mice.

[0085] 1.2 Identification of mouse genotype:

[0086] The offspring of transgenic mice obtained by breeding were taken, and the genomic DNA was extracted as a template for PCR identification. Specific PCR amplification primers were designed to determine the genotype of the offspring mice.

[0087] S1. Extraction of genomic DNA:

[0088] The toe-cutting and numbering method was adopted (the toes of offspring mice 5-6 days after birth were cut), and the toes were numbered from the hind limbs to the forelimbs, and from right to left. The cut toe tissue was used to extract genomic DNA. The general steps of genomic DNA extraction are as follows:

[0089] (1) Take the mouse toes (in order of 1-10) and place them in a 1.5 mL EP tube. Centrifuge for 30 seconds to allow them to settle to the bottom of the tube.

[0090] (2) Add 30 μl of lysis buffer (0.5% 20% Tween-20, 1M KCL 50 mM, 1M MgCl2 15 mM, 1M Tris-HCl 2.5 mM, pH 8.0, add 3 μl of 200 μg / mL proteinase K before use);

[0091] (3) Digest at 55°C for 3-5h, centrifuge at 12,000 rpm for 2min, inactivate proteinase K at 95°C for 15min, and centrifuge at 12,000 rpm for 2min. The DNA in the supernatant was used as a PCR template and stored at -20°C for genotype identification.

[0092] S2. Design of PCR primers and construction of reaction system:

[0093] The primer sequences for APP / PS1 double transgenic mice are as follows:

[0094] 5'-GAC TGA CCA CTC GAC CAG GTT CTG-3' (SEQ ID NO: 2);

[0095] 5'-CTT GTAAGT TGG ATT CTC ATA TCC G-3' (SEQ ID NO: 3);

[0096] 5'-AAT AGA GAA CGG CAG GAG CA-3' (SEQ ID NO: 4);

[0097] 5'-GCC ATG AGG GCA CTA ATC AT-3' (SEQ ID NO: 5).

[0098] The PCR reaction system is:

[0099] Total 20uL PS1: 608 bp; APP: 350 bp 2×Taq Master Mix (Dye Plus) 10uL Primer1 0.5uL Primer2 0.5uL Primer5 0.5uL Primer6 0.5uL <![CDATA[ddH2O]]> 6uL DNA 2uL

[0100] The PCR reaction conditions were: 95°C for 10 min, 95°C for 5 s, 62°C for 30 s, 75°C for 45 s, 30 cycles, 72°C for 5 min, and storage at 4°C. The PCR products were subjected to 2% agarose gel electrophoresis and photographed using a Bio Rad gel electrophoresis imager.

[0101] The 18 mice were identified by double PCR method. Figure 2 As shown in the figure, it can be seen that the mice with numbers 3 to 4, 6, 8 to 9, 11 to 14, 16, and 18 that simultaneously amplified target bands with molecular weights of 608 bp and 350 bp are APP / PS1 double transgenic mice.

[0102] Example 2: Construction and verification of Alzheimer's disease model mice with overexpression of PGC-1α in the hippocampal DG region

[0103] In this example, a mouse model of Alzheimer's disease with overexpression of PGC-1α in the DG region of the hippocampus was constructed, and experiments were performed to verify that PGC-1α was successfully overexpressed in the hippocampus of Alzheimer's disease mice. The specific steps are as follows:

[0104] (1) Construction of PGC-1α overexpression model mice:

[0105] This embodiment is based on Figure 3 The method of inducing PGC-1α overexpression in the hippocampus of Alzheimer's disease mice is as follows:

[0106] Six-month-old APP / PS1 double transgenic mice were anesthetized with 1% pentobarbital and fixed on a brain stereotaxic apparatus. The hair on the top of the head was removed, the skin was disinfected, and a midline incision was made on the top of the head to expose the bregma. According to the atlas of Paxinos and Watson stereotaxic atlas of mice, the following coordinates were noted: bregma (AP) -2.06 mm, midline (ML) ± 1.70 mm, depth (DV) -2.00 mm. The microinjection needle was inserted vertically from the brain surface to -2.0 mm. The overexpression vector pAAV-MCS-Ppargc1α-m-FLAG-HA (see the atlas) was inserted into the brain stereotaxic apparatus. Figure 1 The virus was injected into the hippocampus of mice with Alzheimer's disease at a rate of 0.5 μL per side. The needle was retained for 5 minutes after the injection and then slowly withdrawn. The whole process did not exceed 60 minutes. All operations were performed under sterile conditions, penicillin was used to treat the skin incision, and the window was sutured to induce PGC-1α overexpression in the hippocampus of Alzheimer's disease mice, and PGC-1α overexpression model mice were obtained.

[0107] (2) Verification of PGC-1α overexpression in the hippocampus of Alzheimer's disease double transgenic mice:

[0108] APP / PS1 double transgenic mice were selected and AAV-Vector / AAV-Ppargc1α was injected into the hippocampus (see Figure 3), 25 days later (virus-mediated protein expression was stable), the mice were perfused by heart, brain tissues of the two groups of mice were fixed in 4% paraformaldehyde for 48 h, dehydrated with ethanol gradient, transparentized with xylene, embedded in paraffin wax, and made into 6 μm thick coronal sections. The sections were routinely dewaxed to water, nuclei were stained with hematoxylin, cytoplasm was stained with eosin, dehydrated, transparentized, and sealed; neutral resin was used to seal the sections, and the pathological sections were scanned by a pathological section scanner, observed and photographed to determine the correctness of the perfusion site. The results are shown in Figure 4 shown.

[0109] Figure 4 This is the HE staining verification image of the injection site in the hippocampus of APP / PS1 mice. Figure 4 It can be seen that the perfusion site is the DG area of ​​the hippocampus.

[0110] The brain tissue of mice after microperfusion was fixed in 4% paraformaldehyde for 48 hours, dehydrated with ethanol gradient, transparentized with xylene, and routinely embedded in paraffin to make 6μm thick coronal sections. The sections were routinely dewaxed to water, microwaved for antigen repair, cooled to room temperature and washed 3 times with PBS, 0.3% Triton X-100 (prepared in PBS) was penetrated and punched for 30 minutes, blocked with blocking solution for 1.5 hours, incubated with mouse monoclonal HA primary antibody (1:200) in a 4℃ refrigerator overnight, washed with PBS, incubated with DyLight 488-goat anti-mouse IgG (1:250) for 1.5 hours, stained with DAPI for 10 minutes, operated in a dark environment, washed with PBS, and sealed; sealed with anti-fluorescence quenching sealing agent, and the number of HA-positive cells in the target brain area was observed under a fluorescence microscope. Figure 5 As shown in a.

[0111] Figure 5 This is a verification diagram of PGC-1α overexpression in the hippocampus of APP / PS1 mice. Figure 5 As can be seen in a, compared with AD mice microinfused with AAV-Vector, the number of HA-labeled PGC-1α positive cells in the hippocampus of AD mice microinfused with AAV-Ppargc1α was significantly increased.

[0112] The hippocampal tissue of the mice after microperfusion was obtained, and the protein expression of PGC-1α in this brain region was detected by Western Blotting technology. The specific operations were as follows: protein denaturation, quantification, loading, electrophoresis, membrane transfer, and blocking. After adding rabbit polyclonal PGC-1α primary antibody (1:1,000) and incubating at 4°C overnight, HRP-labeled goat anti-rabbit secondary antibody (1:1,000) was added and incubated at room temperature for 1 hour, and the ECL analysis system BioMax MR was used to acquire images. The protein expression was statistically analyzed using Bio-Rad Quality One analysis software. Western blotting technology was used to monitor the expression and quantification of PGC-1α protein. The results are shown in Figure 2. Figure 5 As shown in b.

[0113] from Figure 5 As can be seen in b, compared with AD mice microperfused with AAV-Vector, the expression of PGC-1α protein in the hippocampus of AD mice microperfused with AAV-Ppargc1α was significantly increased.

[0114] In summary, PGC-1α protein was successfully induced to overexpress in the hippocampus of APP / PS1 mice.

[0115] Example 3: PGC-1α promotes the activation and proliferation of hippocampal neural stem cells in Alzheimer's disease mice

[0116] In this example, the effect of PGC-1α overexpression on the activation and proliferation of hippocampal neural stem cells in Alzheimer's disease mice was detected by immunofluorescence to evaluate the effect of PGC-1α on the activation and proliferation of Type I cells (labeled by GFAP) in the progression of the neurogenesis lineage in Alzheimer's disease. + SOX2 + ) regulation.

[0117] In this example, immunofluorescence was used to monitor GFAP expression in quiescent neural stem cells. + SOX2 + PCNA - and activated neural stem cells GFAP + SOX2 + PCNA + The cell number and immunofluorescence detection method are as shown in Example 2. The antibodies used are: mouse monoclonal SOX2 primary antibody (1:800), mouse monoclonal GFAP primary antibody (1:1,200), rabbit polyclonal PCNA (1:500), DyLight 594-goat anti-mouse IgG, DyLight 488-goat anti-rabbit IgG (1:250). The detection results are as shown in Figure 6 shown.

[0118] from Figure 6 It can be seen that compared with the AD mice microinfused with AAV-Vector, the number of quiescent neural stem cells in the hippocampus of AD mice microinfused with AAV-Ppargc1α (SOX2 + GFAP + PCNA - ) was significantly reduced, while the number of activated neural stem cells (SOX2 + GFAP + PCNA + ) increased significantly.

[0119] This example also uses immunofluorescence to monitor neural stem cells (SOX2 + GFAP +), the immunofluorescence detection method is as shown in Example 2, the antibodies used are: mouse monoclonal SOX2 primary antibody (1:800), rabbit polyclonal GFAP primary antibody (1:100), DyLight 594-goat anti-rabbit IgG, DyLight 488-goat anti-mouse IgG (1:250), the detection results are as shown in Figure 7 shown.

[0120] from Figure 7 It can be seen that compared with the AD mice microperfused with AAV-Vector, AAV-Ppargc1α microperfusion can significantly induce the expression of GFAP in the hippocampus neural stem cells of AD mice. + SOX2 + ) increased in number, indicating that PGC-1α expanded the neural stem cell pool.

[0121] In summary, PGC-1α overexpression promotes the activation of neural stem cells (SOX2 + GFAP + PCNA + ) and significantly induced the number of hippocampal neural stem cells in AD mice (SOX2 + GFAP + ) increase.

[0122] Example 4: Effect of PGC-1α on the proliferation of hippocampal neural progenitor cells in Alzheimer's disease mice

[0123] In this example, the effect of PGC-1α on the proliferation of hippocampal neural progenitor cells in Alzheimer's disease mice was investigated by immunofluorescence to evaluate the effect of PGC-1α on Type II cells (labeled as Tbr2) in the progression of the neurogenesis lineage of Alzheimer's disease. + ) regulation.

[0124] The immunofluorescence detection method is as shown in Example 2, and the antibodies used are: rabbit polyclonal Tbr2 primary antibody (1:200), mouse monoclonal PCNA (1:500), DyLight 594-goat anti-rabbit IgG, and DyLight 488-goat anti-mouse IgG (1:250). Figure 8 The antibodies used in Western blotting include: rabbit polyclonal Tbr2 primary antibody (1:1,000), rabbit polyclonal PCNA (1:5,000), β-Tubulin (1:3,000), HRP-labeled goat anti-rabbit secondary antibody (1:1,000). The test results are shown in Figure 8 shown.

[0125] Figure 8The figure shows that PGC-1α promotes the proliferation of hippocampal neural progenitor cells in Alzheimer's disease mice. As can be seen from the figure, compared with the AD mice microinfused with AAV-Vector, the number of neural progenitor cells in the hippocampus of the AD mice microinfused with AAV-Ppargc1α (Tbr2 + PCNA + ) increased significantly. It can be seen that PGC-1α overexpression promotes the hippocampal committed progenitor cells (Tbr2 + PCNA + )'s proliferation and protein expression (Tbr2) were increased.

[0126] Example 5: Effect of PGC-1α on the differentiation of immature and mature neurons in the hippocampus of Alzheimer's disease mice

[0127] This example investigates the effect of PGC-1α on the differentiation of immature and mature neurons in the hippocampus of Alzheimer's disease mice by immunofluorescence.

[0128] The immunofluorescence detection method is as shown in Example 2, and the antibodies used are: rabbit polyclonal DCX primary antibody (1:300), mouse monoclonal NeuN (1:300), DyLight 594-goat anti-mouse IgG, DyLight 488-goat anti-rabbit IgG (1:250). Fig. 9 The antibodies used in Western blotting include: rabbit polyclonal DCX primary antibody (1:1,000), rabbit polyclonal NeuN primary antibody (1:300), β-Tubulin (1:3000), GAPDH (1:5,000), HRP-labeled goat anti-rabbit secondary antibody (1:1,000). Fig. 9 shown.

[0129] Fig. 9 This is the result of PGC-1α promoting the differentiation of immature and mature neurons in the hippocampus of Alzheimer's disease mice. Fig. 9 As can be seen in ab, compared with the AD mice microinfused with AAV-Vector, the neural progenitor cells (DCX + NeuN - ), immature neurons (DCX + NeuN + ) and mature neurons (DCX - NeuN + ) have increased significantly. Fig. 9 It can be seen from cd that PGC-1α significantly increased the protein expression of DCX and NeuN in the DG region of the hippocampus of AD mice.

[0130] In summary, the present invention has experimentally found that supplementing PGC-1α protein in the mouse brain region can promote neurogenesis in the mouse hippocampus and induce neural stem cells to generate new neurons; the reagent that induces overexpression of PGC-1α protein can be used to prepare drugs that promote hippocampal neurogenesis and supplement lost neurons; the reagent that induces overexpression of PGC-1α protein can expand the pool of neural stem cells in the hippocampus of Alzheimer's disease, promote the transformation of quiescent neural stem cells in the hippocampus of Alzheimer's disease into activated neural stem cells, promote the proliferation of intermediate progenitor cells in the hippocampus of Alzheimer's disease, induce the differentiation of immature neurons in the hippocampus of Alzheimer's disease, induce the generation of mature neurons in the hippocampus of Alzheimer's disease, supplement lost neurons, and improve the impaired neurogenesis in Alzheimer's disease. The present invention has found that the newborn neurons induced by PGC-1α supplement the neuronal loss associated with neurodegeneration, provide new drug targets for delaying the progression or treatment of Alzheimer's disease, and are of great significance to the mechanism research of Alzheimer's disease and the development of targeted drugs.

[0131] The embodiments are preferred implementations of the present invention, but the present invention is not limited to the above-mentioned implementations. Any obvious improvements, substitutions or modifications that can be made by those skilled in the art without departing from the essential content of the present invention belong to the protection scope of the present invention.

Claims

1. Application of PGC-1α in the preparation of drugs for promoting hippocampal neurogenesis and replenishing lost neurons.

2. The use according to claim 1, characterized in that: The nucleotide sequence of PGC-1α is shown in SEQ ID No.

1.

3. A drug for promoting hippocampal neurogenesis and replenishing lost neurons, characterized in that: The drug includes PGC-1α protein, an agonist of PGC-1α or an agent that induces overexpression of PGC-1α through transgenesis.

4. The drug according to claim 3, characterized in that The drugs also include reagents related to adeno-associated virus-induced PGC-1α transgene.

5. The drug according to claim 3 or 4, characterized in that The medicine also includes pharmaceutically acceptable excipients.

6. The drug according to claim 5, characterized in that The pharmaceutically acceptable excipient is selected from at least one of a buffer, an encapsulating agent, a filler, a binder, a transdermal absorbent, a wetting agent, a disintegrant, an absorption promoter, a surfactant, a colorant, a flavoring agent and an adsorption carrier.

7. Use of the drug for promoting hippocampal neurogenesis and replenishing lost neurons as claimed in claim 3 in the preparation of drugs for treating neurological diseases; the neurological diseases include diseases caused by neuronal apoptosis, necrosis or impaired neurogenesis.

8. The use according to claim 7, characterized in that: The neurological disease includes Alzheimer's disease.

9. The use according to claim 7, characterized in that: The applications include: (1) expanding the pool of neural stem cells in the hippocampus of Alzheimer's disease; and / or (2) promoting the transformation of quiescent neural stem cells in the hippocampus of Alzheimer's disease into activated neural stem cells; and / or (3) promoting the proliferation of intermediate progenitor cells in the hippocampus of Alzheimer's disease; and / or (4) inducing differentiation of immature neurons in the hippocampus of Alzheimer's disease; and / or (5) Inducing the generation of mature neurons in the hippocampus of Alzheimer's disease to replenish lost neurons; and / or (6) Improve the impaired neurogenesis in Alzheimer's disease.

10. A drug for treating Alzheimer's disease, characterized in that: The drug includes the drug for promoting hippocampal neurogenesis and replenishing lost neurons as described in claim 3.